Greenphire CEO Selected as Finalist in Ernst & Young Awards
News May 17, 2013
The awards recognize entrepreneurs that create and build market-leading businesses, taking standards of excellence to new heights and helping to transform the face of their respective industries. Sam was chosen from over 70 executives as a finalist for his achievements in building Greenphire into an industry leader.
Sam Whitaker, CEO of Greenphire, comments, "I am delighted to have been selected as a finalist by Ernst & Young and to be honored along with fellow nominees. As Greenphire grows and expands internationally, it is gratifying to be recognized for our successes in transforming outdated processes in the clinical trials industry. It would not have been possible without the tireless work of all the team members at Greenphire."
Since founding Greenphire, Sam has leveraged his entrepreneurial vision to simplify processes within clinical studies, replacing burdensome manual methods with platform-driven tools that execute complex payment processes globally. In five years he has built Greenphire from a two-person concept-driven start-up to an established player in the industry. The company now employs approximately 50 people on two continents.
Awards will be presented at a black tie gala on June 20 at the Pennsylvania Convention Center.
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
Immune Response Restored in Patients with Melanoma Thanks to New CompoundNews
A novel compound may restore immune response in patients with melanoma, according to a study presented at the ESMO Immuno Oncology Congress 2017.READ MORE